At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Gemcitabine +3 moredrug
Likely dose
Gemcitabine 1000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Abraxane, and 2 other interventions for Pancreatic Adenocarcinoma. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Adenocarcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedApr 2013
Primary CompletionApr 2017
Study CompletionJul 2017
TodayJul 2026
First PostedApr 25, 2013
Enrollment StartApr 1, 2013
Primary CompletionApr 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 13.2 years ago
Interventions
Gemcitabinedrug
1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
Abraxanedrug
125 mg/m2 IV over 30 minutes, day 1, 8, 15
FOLFIRINOXdrug
Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
Chemoradiationradiation